AbbVie (ABBV)
$173.15
0.46 (0.26%)
ABBV Stock Quote Delayed 30 Minutes
10 Oversold Stocks to Run From
Wells Fargo, HP and Gilead Sciences are just three oversold stocks to sell before they lose any more ground.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2.93M
Day's Range
$172.77 - $174.59
52-Week Range
$135.85 - $182.89
Dividend & Yield
$5.92 (3.42%)
ABBV Stock Predictions, Articles, and AbbVie News
Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons
ABBV stock offers huge reward with its 5.3% dividend yield, and also huge risk with Humira's generic competition. What's the right play?
Why You Should Buy ABBV Stock for Income and Value
Although there could be further weakness in the AbbVie stock price in the coming months, ABBV stock belongs in a diversified portfolio.
ABBV Stock Is Worth a Look at Multi-Year Lows
The combination of valuation and yield makes ABBV stock a bargain following earnings that were only a slight disappointment.
AbbVie Earnings: ABBV Stock Falters on Q4 Miss
AbbVie earnings for the fourth quarter of 2018 saw ABBV stock falling today after reporting an earnings per share and revenue miss.
As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock
AbbVie has tools with which to mask a slowdown in Humira sales, and an extensive drug pipeline, but the risks in the stock are rising
The Humira Overhang Can’t Cast a Shadow on AbbVie Stock Forever
If you're thinking about stepping into AbbVie stock here, you're not crazy. The challenge is simply getting everyone else to believe in ABBV stock.
AbbVie Stock: 3 Pros and 3 Cons to Consider Before Investing in ABBV
AbbVie has significant challenges, but they’re also not unique ones. Sizing up the outlook leads to a slightly bullish stance on ABBV stock.
AbbVie Stock Has a $10 Upside Opportunity — Buy It Now
There is a $10 technical opportunity in ABBV stock just around the corner. Get on board AbbVie while the value is still reasonable.
